Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC
Status:
Recruiting
Trial end date:
2028-03-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm phase II study of bipolar androgen therapy (BAT) given in
addition with standard of care Sipuleucel-T to determine the interferon (IFN) gamma
Enzyme-linked Immunospot (ELISPOT) response rate to PA2024 (an engineered fusion protein of
prostatic acid phosphatase and granulocyte-macrophage colony-stimulating factor which the
activated autologous dendritic cells in the Sipuleucel-T vaccine are loaded with) in patients
with metastatic castration resistant prostate cancer (mCRPC).